This company did it the right way by getting EU approval first and then seeking investors outside the market. A fraction of share outstanding compared to POH. Now seeking FDA approval. Just heard the CEO talking about it. He said companies overstate the importance of efficacy to regulator (EU & FDA). The regulators are more concerned with long term safety. I know, If only and what ifs ....Pointless now other than to educate for future investments.
Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
Ann: Phosphagenics Arbitration Award Issued, page-144
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(20.0%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $2 | 1.126K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 34751789 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 40153304 | 27 |
View Market Depth
| Last trade - 12.40pm 08/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |